Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTB323 in treatment-resistant generalized myasthenia gravis
2024-513589-20-00Phase 2Suspended
- Sponsor
- Novartis
- Start
- Jul 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of rapcabtagene autoleucel in generalized myasthenia gravis (gMG), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started Jul 2025; status: suspended.
02
Drugs
rapcabtagene autoleucel
03
Conditions
generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on 2024-513589-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513589-20-00.